Welcome to Unmute MS – A new educational podcast series developed by Novartis Pharmaceuticals UK Ltd.
Uncover the biggest questions in multiple sclerosis (MS) and join the conversation that’s shaping the future for patients and clinicians.
Developed for UK healthcare professionals to listen to on-demand, this series of podcasts unpicks the latest insights and current thinking around the questions you most want unmuted in MS.
In the first series, nine episodes explore topics including:
Unmute MS speakers and weekly episodes in Series 1
Dr Agne Straukiene – Consultant Neurologist
Torbay and South Devon NHS Foundation Trust
- What part does technology have to play in the future of MS healthcare?
- How vital is the role of health and wellbeing to patient outcomes in MS?
Dr David Rog – Consultant Neurologist
Salford Royal NHS Foundation Trust
- COVID-19 and MS: a once-in-a-generation opportunity to instigate change?
Dr Wallace Brownlee – MS Specialist Neurologist
National Hospital for Neurology and Neurosurgery, Queen Square
- Diagnosing and defining Secondary Progressive MS – when is the time right?
- Managing people with SPMS – what does the future hold?
Dr Ronan Burke – Clinical Psychologist
National Hospital for Neurology and Neurosurgery, Queen Square
- Opening the mental health conversation – how do psychologists support people with MS?
- How can MS services best support patients’ mental health?
Professor Paul Matthews – Head of Department of Brain Sciences
Imperial College London
- What can imaging tell us about MS pathology?
- How does imaging impact clinical practice? Predicting, monitoring and progression.
The series is available on most major podcast platforms. Subscribe to the podcast and join the community here:
Alternatively, to subscribe manually, please navigate to ‘add show by URL’ in your podcast app, and paste in the URL:
www.kaltura.com/api_v3/getFeed.php?partnerId=2076321&feedId=1_cxcetiv9
You can also listen to the Unmute MS here:
Unmute MS was created and funded by Novartis Pharmaceuticals UK Ltd and is intended for UK healthcare professionals.
MS, multiple sclerosis; SPMS, secondary progressive multiple sclerosis